Retraction
Targeting CD137 enhances the efficacy of cetuximab
Paper Information
Record ID:
20570
Author(s):
Holbrook E Kohrt
A Dimitrios Colevas
Roch Houot
Kipp Weiskopf
Matthew J Goldstein
Peder Lund
Antona Mueller
Idit Sagiv-Barfi
Aurelien Marabelle
Ruth Lira
Emily Troutner
Lori Richards
Amanda Rajapaska
Jonathan Hebb
Cariad Chester
Erin Waller
Anton Ostashko
Wen Kai Weng
Lieping Chen
Debra Czerwinski
Yang Xin Fu
John Sunwoo
Ronald Levy
A Dimitrios Colevas
Roch Houot
Kipp Weiskopf
Matthew J Goldstein
Peder Lund
Antona Mueller
Idit Sagiv-Barfi
Aurelien Marabelle
Ruth Lira
Emily Troutner
Lori Richards
Amanda Rajapaska
Jonathan Hebb
Cariad Chester
Erin Waller
Anton Ostashko
Wen Kai Weng
Lieping Chen
Debra Czerwinski
Yang Xin Fu
John Sunwoo
Ronald Levy
Journal:
Publication Date:
May 16, 2014
Retraction Date:
June 03, 2019
(6.5 years years ago)
Subjects:
Institutions:
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA
- CHU Rennes, Service Hématologie Clinique, Rennes, France
- INSERM, U917, Rennes, France
- Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052, CNRS 5268, Centre Léon Bérard, Université de Lyon, Lyon, France
- Department of Immunobiology, Yale Cancer Center, New Haven, Connecticut, USA
- Department of Pathology and Committee on Immunology, University of Chicago, Chicago, Illinois, USA
Countries:
Article Type:
Publisher:
American Society for Clinical Investigation
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (149)
149
Total Citations24
Post-Retraction(16.1%)
108
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
8
Within 1 year
8
After 2+ years
2038
Days since retraction (latest)
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Dec 2024
2038 days after retraction
Signaling pathways in colorectal cancer implications for the target therapies
Yanlin Song, Ming Chen, Yuhao Wei et al. (5 authors)
Molecular Biomedicine
Open Access
Published: Jun 2024
13 citations
13 citations
1831 days after retraction
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Sep 2022
1199 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Jun 2022
1122 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Feb 2022
974 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Oct 2021
880 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Oct 2021
879 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Oct 2021
868 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: May 2021
698 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Apr 2021
686 days after retraction
Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma
Rolando Pérez‐Lorenzo, S. Erjavec, Angela M. Christiano et al. (4 authors)
Oncotarget
Open Access
Published: Jan 2021
4 citations
4 citations
596 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Jan 2021
578 days after retraction
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
Paola Storti, Federica Costa, Valentina Marchica et al. (8 authors)
Journal of Clinical Medicine
Open Access
Published: Sep 2020
7 citations
7 citations
459 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Aug 2020
455 days after retraction
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
Sachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloeß
Cancers
Open Access
Published: Jul 2020
12 citations
12 citations
399 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Jul 2020
396 days after retraction
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Apr 2020
305 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Apr 2020
305 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Apr 2020
303 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Jan 2020
239 days after retraction
NK Cells in the Tumor Microenvironment
Camille Guillerey
Advances in experimental medicine and biology
Published: Jan 2020
92 citations
92 citations
212 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Dec 2019
181 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Sep 2019
109 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Jul 2019
58 days after retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: May 2019
33 days before retraction
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Apr 2019
51 days before retraction
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Dinh‐Toi Chu, Nguyen Xuan Bac, Khanh Hoang Nguyen et al. (15 authors)
International Journal of Molecular Sciences
Open Access
Published: Apr 2019
77 citations
77 citations
52 days before retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Mar 2019
76 days before retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Mar 2019
88 days before retraction
Paper citing Targeting CD137 enhances the efficacy of cetuximab...
Unknown Authors
Unknown Journal
Published: Mar 2019
91 days before retraction
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Mar 2019
91 days before retraction
Paper citing CD137 stimulation enhances the antilymphoma activi...
Unknown Authors
Unknown Journal
Published: Feb 2019
108 days before retraction
NK cells to cure cancer
Clara Di Vito, Joanna Mikulak, Elisa Zaghi et al. (6 authors)
Seminars in Immunology
Published: Feb 2019
81 citations
81 citations
122 days before retraction
Quick Stats
Total Citations:
149
Years Since Retraction:
6.5 years
Open Access:
Yes
Last Checked:
Never